You are here: Home: Audio Program Guide: LCU 4 | 2007 Audio: LCU 4 | 2007

   
  To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
Curran, MD Walter J Curran Jr, MD
Professor and Chairman
Department of Radiation Oncology
Deputy Director for Clinical Sciences
Kimmel Cancer Center of Jefferson Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

  
  Click here to download entire interview  
Track 1 EORTC study of prophylactic cranial irradiation (PCI) versus no PCI in extensive-disease small cell lung cancer (SCLC) after response to chemotherapy
Track 2 Clinical implications of the EORTC PCI trial results
Track 3 Neurologic and cognitive side effects of cranial irradiation
Track 4 Mortality and disability from brain metastases in extensive-disease SCLC
Track 5 Integration of bevacizumab with chemoradiation therapy for patients with solid tumors
Track 6 Potential risks and benefits of chemoradiation therapy with bevacizumab in lung cancer
Track 7 ECOG-E1505 evaluating adjuvant chemotherapy with or without bevacizumab in
Stage IB to IIIA NSCLC
Track 8 Role of adjuvant chemotherapy for patients with Stage IB NSCLC
Track 9 Clinical and molecular predictors of response to erlotinib
Track 10 Quality of life with erlotinib versus chemotherapy
Track 11 Implications of the HOG LUN 01-24 trial results: Docetaxel consolidation in Stage III NSCLC
Track 12 Risk of relapse after chemoradiation therapy in Stage III NSCLC
Track 13 SWOG-S0023: Maintenance gefitinib or placebo after chemoRT/docetaxel for patients with Stage III NSCLC
Track 14 Proposed RTOG study of higher-dose radiation therapy in Stage III NSCLC audio
 
Rogerio C Lilenbaum, MD Rogerio C Lilenbaum, MD
Clinical Associate Professor of Medicine
University of Miami School of Medicine
Director, Thoracic Oncology Program
The Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
  
  Click here to download entire interview  
Track 1 Case discussion: A 62-year-old woman with Stage IV SCLC
Track 2 CALGB-30306: A Phase II study of cisplatin/irinotecan with bevacizumab for extensive-stage SCLC
previously untreated with chemotherapy
Track 3 Tumor response in trials evaluating cisplatin/irinotecan with bevacizumab
Track 4 Clinical use of PCI for SCLC
Track 5 Treatment options for brain metastases
Track 6 Efficacy of PCI in extensive-stage SCLC
Track 7 Case discussion: A 73-year-old woman, never smoker, treated with single-agent erlotinib for
advanced NSCLC
Track 8 Treatment of progressive disease after 18 months of erlotinib monotherapy
Track 9 Phase III study of second-line docetaxel with or without vandetanib for patients with locally advanced
or metastatic NSCLC
Track 10 Phase II study of gemcitabine/oxaliplatin with or without bevacizumab for advanced NSCLC
Track 11 Case discussion: A 30-year-old woman, nonsmoker, with adenocarcinoma of the lung associated with squamous cell carcinoma of the bone
Track 12 Clinical course of cisplatin/docetaxel with bevacizumab
Track 13 Treatment with maintenance erlotinib/bevacizumab after chemotherapy/bevacizumab
Track 14 Incidence of lung cancer among nonsmokers and oligosmokers
Track 15 CALGB-30406: A Phase II randomized study of erlotinib with or without carboplatin/ paclitaxel for chemotherapy-naïve Stage IIIB or IV NSCLC Audio
Track 16 Use of adjuvant erlotinib for nonsmokers with an EGFR mutation Audio
Track 17 Case discussion: A 77-year-old man treated with adjuvant cisplatin and docetaxel for Stage IIB NSCLC Audio
Track 18 Tolerability of adjuvant chemotherapy in elderly patients Audio
Track 19 Rationale for combining docetaxel with cisplatin in the adjuvant setting Audio
Track 20 Natural history of NSCLC after surgery and adjuvant therapy Audio
 
Edelman, MD Martin J Edelman, MD
Professor of Medicine
Director of Medical Thoracic Oncology
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland

  
  Click here to download entire interview  
Track 1 Approaches to chemoRT for Stage III NSCLC
Track 2 HOG LUN 01-24: Cisplatin/etoposide and concurrent radiation therapy with or without consolidation
docetaxel for inoperable Stage III NSCLC
Track 3 Scientific and clinical interpretation of the SWOG-S0023 trial results
Track 4 Clinical algorithm for the use of erlotinib in patients with metastatic NSCLC
Track 5 Investigation of adjuvant erlotinib in target-enriched patient populations
Track 6 Clinical use of adjuvant erlotinib for nonsmokers with an EGFR gene mutation
Track 7 Clinical implications of HOG LUN 01-24
Track 8 AVAiL: Cisplatin/gemcitabine with or without bevacizumab for chemotherapy-naïve advanced or
recurrent nonsquamous NSCLC
Track 9 Dosing of bevacizumab
Track 10 Tolerability of bevacizumab
Track 11 Selection of first-line therapy for patients with metastatic NSCLC audio
Track 12 Selection of second-line therapy for patients with metastatic NSCLC audio
Track 13 Heterogeneity among PS2 patients: Implications for treatment
Track 14 Use of erlotinib for PS2 patients with no tumor-related symptoms
Track 15 Cisplatin/docetaxel as adjuvant therapy for NSCLC audio
Track 16 Treatment approach for Stage IB disease audio